Saitama Medical University   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Moroyama Japan (1892)

Organization Overview

First Clinical Trial
2006
NCT00288717
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Department of Nephrology, Saitama Medical University | Department of Neurology, Saitama Medical Center, Saitama Medical University, Saitama, Japan | Kosei Hasegawa | Saitama International Medical Center, Saitama Medical University | Saitama Medical School Department of Renal Medicine | Saitama Medical University | Saitama Medical University International Medical Center | Saitama Medical University International Medical Center Comprehensive Cancer Center

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 4)

Arthritis, Rheumatoid (Phase 4)

Carcinoma, Ovarian Epithelial (Phase 3)

Fallopian Tube Neoplasms (Phase 3)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Guillain-Barre Syndrome (Phase 3)

Immunoblastic Lymphadenopathy (Phase 3)

Lymphoma (Phase 3)

Lymphoma, T-Cell (Phase 3)

Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 3)

Syndrome (Phase 3)

Uterine Cervical Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 12
  • # of Trial APIs: 22